Astera Labs (NASDAQ:ALAB) Stock Price Expected to Rise, Barclays Analyst Says

Astera Labs (NASDAQ:ALABGet Free Report) had its price target hoisted by analysts at Barclays from $87.00 to $135.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 1.28% from the company’s current price.

ALAB has been the subject of a number of other research reports. Roth Mkm upped their target price on Astera Labs from $80.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Citigroup initiated coverage on shares of Astera Labs in a research report on Monday, November 18th. They issued a “buy” rating and a $120.00 price target for the company. Northland Securities cut shares of Astera Labs from an “outperform” rating to a “market perform” rating and increased their target price for the stock from $100.00 to $120.00 in a research report on Thursday, January 2nd. Craig Hallum lifted their price target on Astera Labs from $75.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, Northland Capmk lowered shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $109.75.

View Our Latest Stock Analysis on ALAB

Astera Labs Price Performance

ALAB opened at $133.30 on Friday. The stock’s fifty day moving average is $119.56 and its 200-day moving average is $76.54. Astera Labs has a one year low of $36.22 and a one year high of $147.39.

Astera Labs (NASDAQ:ALABGet Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. The firm had revenue of $113.10 million for the quarter, compared to the consensus estimate of $97.50 million. Astera Labs had a negative return on equity of 15.57% and a negative net margin of 30.69%. The company’s revenue was up 47.1% on a year-over-year basis. As a group, equities research analysts predict that Astera Labs will post -0.45 earnings per share for the current fiscal year.

Insider Activity at Astera Labs

In related news, General Counsel Philip Mazzara sold 42,000 shares of Astera Labs stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $96.56, for a total transaction of $4,055,520.00. Following the completion of the sale, the general counsel now owns 258,564 shares in the company, valued at $24,966,939.84. This trade represents a 13.97 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sanjay Gajendra sold 740,000 shares of Astera Labs stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $96.59, for a total value of $71,476,600.00. Following the completion of the transaction, the insider now owns 775,000 shares in the company, valued at $74,857,250. This trade represents a 48.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,690,452 shares of company stock valued at $167,581,256 in the last 90 days.

Hedge Funds Weigh In On Astera Labs

Several hedge funds and other institutional investors have recently bought and sold shares of ALAB. Wesbanco Bank Inc. purchased a new stake in shares of Astera Labs during the fourth quarter worth about $331,000. Dakota Wealth Management increased its position in shares of Astera Labs by 2.5% during the fourth quarter. Dakota Wealth Management now owns 43,110 shares of the company’s stock worth $5,710,000 after acquiring an additional 1,049 shares during the period. Trueblood Wealth Management LLC purchased a new stake in shares of Astera Labs in the 4th quarter valued at approximately $331,000. Mandatum Life Insurance Co Ltd purchased a new position in shares of Astera Labs in the 4th quarter valued at about $462,000. Finally, Oak Ridge Investments LLC acquired a new position in shares of Astera Labs in the 4th quarter valued at $284,000. Institutional investors and hedge funds own 60.47% of the company’s stock.

About Astera Labs

(Get Free Report)

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

Featured Articles

Analyst Recommendations for Astera Labs (NASDAQ:ALAB)

Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.